Cellular response and anti-HBs synthesis in vitro after vaccination with yeast-derived recombinant hepatitis vaccine

Alberto Degrassi, Erminia Mariani, Maria Cristina Honorati, Patrizia Roda, Rita Miniero, Maurizio Capelli, Andrea Facchini

Research output: Contribution to journalArticle

Abstract

Two groups of subjects receiving two different doses of yeast-derived recombinant hepatitis B surface antigen (rHBsAg) (10 μg Gen-HB-Vax, Merck Sharp and Dohme and 20 μg Engerix-B, Smith Kline and French) were investigated for in vitro specific humoral and cellular response to the native protein. In vitro proliferative response was dependent on the following critical variables: (1) antigen-specific precursor lymphocytes were present in the peripheral blood for a very short time; (2) the number of circulating specific precursors was dependent on the dose of HBsAg used for vaccination; (3) the presence of antigen-presenting cells was necessary to obtain a blastogenic response in vitro. In vitro proliferation was enhanced by the addition of recombinant interleukin 2 (rIL-2). Spontaneous and stimulated (anti-CD3, pokeweed mitogen) anti-HBs antibody production in vitro was obtained in only eight out of 20 subjects after the fourth boost. Although a different immunogenicity of the two vaccines cannot be excluded, these data strongly suggest that T and B cells responsive to HBsAg present different kinetics of recirculation in the peripheral blood, depending on the antigen dose used for immunization.

Original languageEnglish
Pages (from-to)617-622
Number of pages6
JournalVaccine
Volume10
Issue number9
DOIs
Publication statusPublished - 1992

Fingerprint

Synthetic Vaccines
hepatitis
Hepatitis
Vaccination
Yeasts
vaccination
vaccines
yeasts
Hepatitis B Surface Antigens
synthesis
dosage
antigens
Phytolacca americana
antigen-presenting cells
blood
antibody formation
interleukin-2
B-lymphocytes
immunization
lymphocytes

Keywords

  • Hepatitis B
  • immune response
  • recombinant hepatitis B surface antigen
  • vaccination

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Cellular response and anti-HBs synthesis in vitro after vaccination with yeast-derived recombinant hepatitis vaccine. / Degrassi, Alberto; Mariani, Erminia; Honorati, Maria Cristina; Roda, Patrizia; Miniero, Rita; Capelli, Maurizio; Facchini, Andrea.

In: Vaccine, Vol. 10, No. 9, 1992, p. 617-622.

Research output: Contribution to journalArticle

Degrassi, Alberto ; Mariani, Erminia ; Honorati, Maria Cristina ; Roda, Patrizia ; Miniero, Rita ; Capelli, Maurizio ; Facchini, Andrea. / Cellular response and anti-HBs synthesis in vitro after vaccination with yeast-derived recombinant hepatitis vaccine. In: Vaccine. 1992 ; Vol. 10, No. 9. pp. 617-622.
@article{fc608909f4e046078fcf3a7f2aaba5d9,
title = "Cellular response and anti-HBs synthesis in vitro after vaccination with yeast-derived recombinant hepatitis vaccine",
abstract = "Two groups of subjects receiving two different doses of yeast-derived recombinant hepatitis B surface antigen (rHBsAg) (10 μg Gen-HB-Vax, Merck Sharp and Dohme and 20 μg Engerix-B, Smith Kline and French) were investigated for in vitro specific humoral and cellular response to the native protein. In vitro proliferative response was dependent on the following critical variables: (1) antigen-specific precursor lymphocytes were present in the peripheral blood for a very short time; (2) the number of circulating specific precursors was dependent on the dose of HBsAg used for vaccination; (3) the presence of antigen-presenting cells was necessary to obtain a blastogenic response in vitro. In vitro proliferation was enhanced by the addition of recombinant interleukin 2 (rIL-2). Spontaneous and stimulated (anti-CD3, pokeweed mitogen) anti-HBs antibody production in vitro was obtained in only eight out of 20 subjects after the fourth boost. Although a different immunogenicity of the two vaccines cannot be excluded, these data strongly suggest that T and B cells responsive to HBsAg present different kinetics of recirculation in the peripheral blood, depending on the antigen dose used for immunization.",
keywords = "Hepatitis B, immune response, recombinant hepatitis B surface antigen, vaccination",
author = "Alberto Degrassi and Erminia Mariani and Honorati, {Maria Cristina} and Patrizia Roda and Rita Miniero and Maurizio Capelli and Andrea Facchini",
year = "1992",
doi = "10.1016/0264-410X(92)90443-N",
language = "English",
volume = "10",
pages = "617--622",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "9",

}

TY - JOUR

T1 - Cellular response and anti-HBs synthesis in vitro after vaccination with yeast-derived recombinant hepatitis vaccine

AU - Degrassi, Alberto

AU - Mariani, Erminia

AU - Honorati, Maria Cristina

AU - Roda, Patrizia

AU - Miniero, Rita

AU - Capelli, Maurizio

AU - Facchini, Andrea

PY - 1992

Y1 - 1992

N2 - Two groups of subjects receiving two different doses of yeast-derived recombinant hepatitis B surface antigen (rHBsAg) (10 μg Gen-HB-Vax, Merck Sharp and Dohme and 20 μg Engerix-B, Smith Kline and French) were investigated for in vitro specific humoral and cellular response to the native protein. In vitro proliferative response was dependent on the following critical variables: (1) antigen-specific precursor lymphocytes were present in the peripheral blood for a very short time; (2) the number of circulating specific precursors was dependent on the dose of HBsAg used for vaccination; (3) the presence of antigen-presenting cells was necessary to obtain a blastogenic response in vitro. In vitro proliferation was enhanced by the addition of recombinant interleukin 2 (rIL-2). Spontaneous and stimulated (anti-CD3, pokeweed mitogen) anti-HBs antibody production in vitro was obtained in only eight out of 20 subjects after the fourth boost. Although a different immunogenicity of the two vaccines cannot be excluded, these data strongly suggest that T and B cells responsive to HBsAg present different kinetics of recirculation in the peripheral blood, depending on the antigen dose used for immunization.

AB - Two groups of subjects receiving two different doses of yeast-derived recombinant hepatitis B surface antigen (rHBsAg) (10 μg Gen-HB-Vax, Merck Sharp and Dohme and 20 μg Engerix-B, Smith Kline and French) were investigated for in vitro specific humoral and cellular response to the native protein. In vitro proliferative response was dependent on the following critical variables: (1) antigen-specific precursor lymphocytes were present in the peripheral blood for a very short time; (2) the number of circulating specific precursors was dependent on the dose of HBsAg used for vaccination; (3) the presence of antigen-presenting cells was necessary to obtain a blastogenic response in vitro. In vitro proliferation was enhanced by the addition of recombinant interleukin 2 (rIL-2). Spontaneous and stimulated (anti-CD3, pokeweed mitogen) anti-HBs antibody production in vitro was obtained in only eight out of 20 subjects after the fourth boost. Although a different immunogenicity of the two vaccines cannot be excluded, these data strongly suggest that T and B cells responsive to HBsAg present different kinetics of recirculation in the peripheral blood, depending on the antigen dose used for immunization.

KW - Hepatitis B

KW - immune response

KW - recombinant hepatitis B surface antigen

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=0026749786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026749786&partnerID=8YFLogxK

U2 - 10.1016/0264-410X(92)90443-N

DO - 10.1016/0264-410X(92)90443-N

M3 - Article

C2 - 1386954

AN - SCOPUS:0026749786

VL - 10

SP - 617

EP - 622

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 9

ER -